Association between donor CD3+ T-cell chimerism at day 28 and subsequent acute GVHD
. | No. of patients with grades 2 to 4 acute GVHD/no. patients at risk*(%) . | . | |
|---|---|---|---|
| T-cell chimerism, % . | Day 14 . | Day 28 . | |
| 0 to 50 | 11/30 (37) | 4/15 (27) | |
| 51 to 75 | 21/39 (54) | 9/27 (33) | |
| 75 to 90 | 17/21 (81) | 10/24 (42) | |
| 91 to 100 | 2/6 (33) | 6/8 (75) | |
. | No. of patients with grades 2 to 4 acute GVHD/no. patients at risk*(%) . | . | |
|---|---|---|---|
| T-cell chimerism, % . | Day 14 . | Day 28 . | |
| 0 to 50 | 11/30 (37) | 4/15 (27) | |
| 51 to 75 | 21/39 (54) | 9/27 (33) | |
| 75 to 90 | 17/21 (81) | 10/24 (42) | |
| 91 to 100 | 2/6 (33) | 6/8 (75) | |
P values obtained from trend test in a logistic regression model that adjusted for presence of an unrelated donor were as follows: day 14, P = .06, and day 28, P = .02.
Day-28 T-cell chimerism data were available for 74 of 84 patients alive without GVHD on day 28.